# PrimeLink

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/primelink

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Total disclosed funding: $14M
- Latest round: Angel (Nov 25, 2022)
- Investors on record: 3

## About

Established in 2021 and based in Shenzhen, China, PrimeLink operates as a drug developer that focuses on medical and health services, and drug delivery systems and antibody-coupled drugs (ADCs) R&D. The company's R&D center located in Suzhou industrial park. It has more than 20 employees and more than 50% of the core research team has doctor's degree. Dr. Yin is the founder of the company, and has nearly 20 years of ADC drug development experience, and was the core inventor of Mersana's first and second generation linker.

The company provides ADC drug pool platform. It focuses on the establishing first in class & best in class product pipeline. ADC Drugs includes four components : antibodies, biocouples, connectors and payloads.

## Funding rounds

- Angel, Nov 25, 2022, $14M — Kaitai Capital, Vertex Ventures China, Fosun Health Capital

## Investors

- Kaitai Capital (https://capitalatlas.ai/funds/kaitai-capital) — Angel
- Vertex Ventures China (https://capitalatlas.ai/funds/vertex-ventures-china) — Angel
- Fosun Health Capital (https://capitalatlas.ai/funds/fosun-health-capital) — Angel